Stock listing
Dusseldorf:9EN Pharvaris N.V. Aktie
German listing (Dusseldorf) of Pharvaris N.V. · home listing NASDAQ:PHVS
Follow Pharvaris N.V. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PHVS
$31.28 USD -0.27 (-0.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PHVS
- Day range
- $30.43 – $31.99 USDNov 20, 2026
- Volume
- 463,997 sharesNov 20, 2026
- Market cap
- $2.20B USDAt the close on Nov 20, 2026 · price × 70.20M shares outstanding
- 52-week range
- $23.15 – $43.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $26.10M USDMedian day 627,797 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PHVS · Home | $31.28 USD | -0.27 (-0.9%) | 463,997 | $31.41 | $31.99 | $30.43 | $31.55 | Close on Nov 20, 2026 |
| Frankfurt:9EN | €28.45 EUR | -0.30 (-1.0%) | — | €28.30 | €28.65 | €27.65 | €28.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHVS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $31.28 | -0.27 | -0.9% | $31.41 | $31.99 | $30.43 | 463,997 | |
| $31.55 | -0.73 | -2.3% | $32.24 | $32.63 | $31.22 | 390,162 | |
| $32.28 | -0.16 | -0.5% | $32.00 | $32.42 | $31.29 | 241,403 | |
| $32.44 | -0.92 | -2.8% | $33.19 | $34.46 | $32.44 | 307,781 | |
| $33.36 | -0.47 | -1.4% | $33.79 | $34.28 | $32.85 | 182,582 | |
| $33.83 | -0.35 | -1.0% | $33.59 | $34.55 | $33.00 | 376,267 | |
| $34.18 | +0.19 | +0.6% | $34.01 | $34.73 | $33.82 | 421,745 | |
| $33.99 | -0.48 | -1.4% | $34.10 | $35.05 | $33.21 | 745,421 | |
| $34.47 | +0.08 | +0.2% | $34.80 | $35.47 | $34.05 | 638,332 | |
| $34.39 | +1.86 | +5.7% | $32.85 | $35.21 | $32.28 | 405,106 | |
| $32.53 | -1.80 | -5.2% | $34.33 | $34.66 | $32.53 | 932,821 | |
| $34.33 | -0.45 | -1.3% | $35.06 | $35.42 | $33.03 | 311,376 | |
| $34.78 | +1.25 | +3.7% | $33.90 | $35.30 | $33.90 | 577,199 | |
| $33.53 | 0.00 | 0.0% | $33.68 | $34.21 | $32.90 | 633,053 | |
| $33.53 | -0.05 | -0.1% | $33.48 | $33.94 | $33.05 | 1,481,526 | |
| $33.58 | +0.76 | +2.3% | $32.84 | $33.62 | $32.70 | 877,867 | |
| $32.82 | +0.87 | +2.7% | $31.79 | $32.86 | $31.74 | 381,071 | |
| $31.95 | +0.41 | +1.3% | $31.62 | $32.34 | $31.59 | 230,114 | |
| $31.54 | +0.13 | +0.4% | $31.38 | $32.08 | $31.30 | 347,674 | |
| $31.41 | +0.73 | +2.4% | $31.57 | $32.12 | $30.25 | 621,710 | |
| $30.68 | +0.02 | +0.1% | $30.76 | $31.02 | $29.84 | 347,236 | |
| $30.66 | -0.24 | -0.8% | $31.22 | $31.50 | $30.55 | 393,583 | |
| $30.90 | +1.13 | +3.8% | $29.83 | $31.60 | $29.83 | 1,029,035 | |
| $29.77 | +2.03 | +7.3% | $27.80 | $29.95 | $27.80 | 917,081 | |
| $27.74 | -1.90 | -6.4% | $29.50 | $29.54 | $27.68 | 1,307,641 | |
| $29.64 | -0.38 | -1.3% | $30.20 | $30.85 | $29.23 | 820,425 | |
| $30.02 | 0.00 | 0.0% | $30.00 | $30.52 | $29.80 | 400,428 | |
| $30.02 | -0.87 | -2.8% | $30.68 | $31.21 | $29.99 | 443,982 | |
| $30.89 | -0.21 | -0.7% | $31.09 | $31.93 | $30.64 | 646,018 | |
| $31.10 | -0.02 | -0.1% | $31.14 | $31.96 | $31.09 | 754,990 | |
| $31.12 | -0.56 | -1.8% | $31.57 | $31.57 | $30.30 | 628,231 | |
| $31.68 | +0.56 | +1.8% | $30.97 | $32.32 | $30.58 | 341,842 | |
| $31.12 | +0.63 | +2.1% | $30.50 | $31.27 | $30.15 | 778,389 | |
| $30.49 | -0.70 | -2.2% | $31.19 | $31.47 | $30.15 | 816,234 | |
| $31.19 | +0.18 | +0.6% | $31.21 | $31.55 | $30.69 | 591,391 | |
| $31.01 | -0.71 | -2.2% | $31.74 | $31.98 | $30.90 | 654,347 | |
| $31.72 | -0.01 | 0.0% | $31.84 | $32.05 | $31.14 | 839,837 | |
| $31.73 | -0.18 | -0.6% | $31.93 | $32.34 | $31.23 | 459,293 | |
| $31.91 | -0.11 | -0.3% | $32.00 | $32.46 | $31.39 | 753,331 | |
| $32.02 | -0.97 | -2.9% | $33.08 | $33.62 | $31.96 | 597,654 | |
| $32.99 | -0.08 | -0.2% | $32.88 | $33.84 | $31.91 | 949,002 | |
| $33.07 | -2.13 | -6.1% | $35.19 | $35.31 | $32.87 | 654,290 | |
| $35.20 | -0.82 | -2.3% | $35.82 | $36.27 | $34.90 | 588,601 | |
| $36.02 | -0.35 | -1.0% | $36.33 | $36.88 | $35.50 | 653,735 | |
| $36.37 | -1.63 | -4.3% | $38.09 | $38.20 | $36.08 | 580,260 | |
| $38.00 | +0.45 | +1.2% | $37.81 | $38.93 | $37.60 | 1,137,444 | |
| $37.55 | -0.51 | -1.3% | $38.12 | $38.38 | $37.00 | 828,999 | |
| $38.06 | -0.80 | -2.1% | $39.12 | $40.00 | $37.75 | 1,751,144 | |
| $38.86 | +0.84 | +2.2% | $38.16 | $40.46 | $38.10 | 998,004 | |
| $38.02 | +0.51 | +1.4% | $38.13 | $40.60 | $37.47 | 1,449,491 | |
| $37.51 | -0.23 | -0.6% | $37.60 | $39.03 | $37.00 | 1,324,987 | |
| $37.74 | -0.10 | -0.3% | $38.26 | $39.18 | $37.05 | 1,427,371 | |
| $37.84 | +2.59 | +7.3% | $40.96 | $43.25 | $37.60 | 6,328,168 | |
| $35.25 | -0.41 | -1.1% | $35.36 | $36.39 | $35.21 | 483,983 | |
| $35.66 | +0.49 | +1.4% | $35.39 | $35.88 | $34.58 | 357,063 | |
| $35.17 | +0.24 | +0.7% | $35.05 | $35.97 | $34.04 | 320,876 | |
| $34.93 | +0.32 | +0.9% | $34.45 | $35.07 | $33.80 | 394,435 | |
| $34.61 | -0.71 | -2.0% | $35.31 | $35.73 | $34.13 | 557,515 | |
| $35.32 | -1.68 | -4.5% | $37.00 | $37.41 | $35.26 | 479,029 | |
| $37.00 | 0.00 | 0.0% | $37.00 | $37.49 | $36.30 | 765,048 | |
| $37.00 | -0.23 | -0.6% | $37.31 | $37.40 | $36.24 | 448,941 | |
| $37.23 | -0.08 | -0.2% | $37.32 | $38.00 | $36.69 | 861,175 | |
| $37.31 | +1.04 | +2.9% | $36.27 | $38.13 | $35.70 | 691,824 | |
| $36.27 | -0.12 | -0.3% | $36.61 | $36.93 | $36.12 | 515,458 | |
| $36.39 | +0.12 | +0.3% | $36.13 | $36.82 | $35.45 | 627,797 |
- Ticker
- Dusseldorf:9EN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Latest deck · October 2026
HAEi Regional Conference Americas 2026
Conference · 5 slides
Latest news
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Nov 12, 2026
Closed $33.83 (-1.0%) on Nov 12, 2026
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 12, 2026
Closed $33.83 (-1.0%) on Nov 12, 2026
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Oct 29, 2026
Closed $33.58 (+2.3%) on Oct 29, 2026
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Oct 5, 2026
Closed $30.49 (-2.2%) on Oct 5, 2026
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Sep 8, 2026
Closed $37.84 (+7.3%) on Sep 8, 2026
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Sep 3, 2026
Closed $35.66 (+1.4%) on Sep 3, 2026
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 12, 2026
Closed $36.46 (+5.9%) on Aug 12, 2026
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Jul 22, 2026
Closed $34.36 (-0.3%) on Jul 22, 2026
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Jul 6, 2026
Closed $33.22 (-1.9%) on Jul 6, 2026
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Jun 15, 2026
Closed $31.54 (+2.7%) on Jun 15, 2026
Pharvaris N.V. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 130 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 21 decks · latest October 2026
Where Pharvaris N.V. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PHVS · Home listing | NASDAQ | United States | USD |
| gettex:9EN | gettex | Germany | EUR |
| LS Exchange:A2QNWS | LS Exchange | Germany | EUR |
| Tradegate:9EN | Tradegate | Germany | EUR |
| BOATS:PHVS | BOATS | United States | USD |
| Lang & Schwarz:A2QNWS | Lang & Schwarz | Germany | EUR |
| Frankfurt:9EN | Frankfurt | Germany | EUR |
| Dusseldorf:9EN · This page | Dusseldorf | Germany | EUR |
| Munich:9EN | Munich | Germany | EUR |
| Stuttgart:9EN | Stuttgart | Germany | EUR |
Valuation
Price/book 7.5× against a median of 3.8×: 8th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.89B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.70B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.26B | US$2.03B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.8M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.00B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Regencell Bioscience Holdings Limited · NASDAQ:RGC | US$2.07B | US$2.06B | n/a | n/a | n/a | 155× | n/a | 0.0× | 1.57 |
| Median of the others | US$2.19B | US$1.71B | 108× | 17.2× | 90.0× | 3.8× | −73.9% | 0.0× | 1.46 |
Forecasts
11 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 58.19 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.61 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Berndt Modig | Chief Executive Officer, Director |
| David Nassif | Chief Financial Officer & Chief Legal Officer |
| Peng Lu | President |
| Maggie Beller | Vice President, Head of Corporate and Investor Communications |
| Anna Nijdam | Head, Strategic Finance and Principal Accounting Officer |
| Anne Lesage | Chief Early Development Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Stefan Abele | Chief Technical Operations Officer |
| Wim Souverijns | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| David Meeker | Chair of the Board |
| Viviane Monges | Director, Audit Chair |
| Berndt Modig | Chief Executive Officer, Director |
| Elisabeth Björk | Director |
| Hans Schikan | Vice Chair of the Board |
| Robert Glassman | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −1.0% |
| Q2 2026 | Aug 12, 2026 · Before open | +5.9% |
| Q1 2026 | Apr 2, 2026 · Before open | −3.0% |
| Q3 2025 | Nov 12, 2025 · Before open | +7.0% |
| Q2 2025 | Aug 12, 2025 · After close | +1.6% |
| Q1 2025 | May 13, 2025 · After close | −0.3% |
| Q3 2024 | Nov 13, 2024 · After close | +2.5% |
| Q2 2024 | Aug 14, 2024 · Before open | −7.5% |
| Q1 2024 | May 8, 2024 · After close | −1.3% |
| Q4 2023 | Mar 6, 2024 · Before open | +5.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 2, 2023 · Before open | +1.6% |
| Q2 2023 | Aug 7, 2023 · Before open | −6.9% |
| Q1 2023 | May 8, 2023 · Before open | +0.1% |
| Q3 2022 | Dec 8, 2022 · Before open | +356.6% |
| Q2 2022 | Sep 12, 2022 · Before open | −0.1% |
| Q1 2022 | May 11, 2022 · Before open | −0.3% |
| Q4 2021 | Mar 29, 2022 · Before open | +1.1% |
| Quarter to Sep 30, 2021 | Nov 10, 2021 · Before open | −4.9% |
| Q2 2021 | Jul 30, 2021 · Before open | +5.2% |
| Quarter to Mar 31, 2021 | May 26, 2021 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| HAEi Regional Conference Americas 2026 | Conference | 5 slides | October 2026 |
| Technical Presentation (September 2026) | Technical | 15 slides | Sep 8, 2026 |
| Investor Presentation (January 2026) | Investor deck | 26 slides | Jan 12, 2026 |
| Technical Presentation (2026) | Technical | 14 slides | 2026 |
| Investor Presentation (January 2025) | Investor deck | 113 slides | Jan 13, 2025 |
| Technical Presentation (2025) | Technical | 12 slides | 2025 |
| Investor Day (October 2024) | Investor day | 32 slides | Oct 23, 2024 |
| Investor Presentation (September 2024) | Investor deck | 54 slides | Sep 5, 2024 |
| Investor Presentation (September 2024) | Investor deck | 37 slides | September 2024 |
| Investor Presentation (January 2024) | Investor deck | 59 slides | Jan 22, 2024 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2023) | Investor deck | 40 slides | Dec 6, 2023 |
| Technical Presentation (December 2023) | Technical | 25 slides | Dec 6, 2023 |
| Investor Presentation (March 2023) | Investor deck | 45 slides | Mar 8, 2023 |
| Investor Presentation (February 2023) | Investor deck | 47 slides | Feb 14, 2023 |
| Investor Presentation (January 2023) | Investor deck | 46 slides | Jan 9, 2023 |
| Technical Presentation (December 2022) | Technical | 33 slides | Dec 8, 2022 |
| Investor Presentation (November 2022) | Investor deck | 45 slides | Nov 1, 2022 |
| Investor Presentation (July 2022) | Investor deck | 31 slides | Jul 13, 2022 |
| Investor Presentation (January 2022) | Investor deck | 33 slides | Jan 10, 2022 |
| Technical Presentation (2021) | Technical | 9 slides | 2021 |
| Technical Presentation | Technical | 13 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Closed: US$201.2M raised · US$20 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), Oppenheimer & Co. (co-lead), Van Lanschot Kempen (co-lead) Use of proceeds: R&D for late-stage clinical programs, hiring a US sales and marketing team and commercialization, working capital and general corporate purposes | Jul 24, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$20.00 a share on Feb 4, 2021.
- Price
- US$20.00 a share
- Shares offered
- 8,270,500 ordinary shares
- Offering size
- US$165.4 million
- Underwriters' option
- Up to 1,240,575 more shares
- Underwriters
- Morgan Stanley, BofA Securities, SVB Leerink, Oppenheimer & Co., Kempen & Co · In the order on the cover
- Shares delivered
- On or about Feb 9, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 12, 2020 |
| Filed publicly | Jan 15, 2021 |
| Amended twice | Newest Feb 1, 2021 |
| Shares registered with an exchange | Feb 4, 2021 |
| Declared effective by the SEC | Feb 4, 2021 |
| Final prospectus, with the price | Feb 8, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 8, 2021 |
| EFFECT · Notice that a registration is effective | Feb 4, 2021 |
| F-1MEF · Registration of more shares for the same offering | Feb 4, 2021 |
| CERT · Exchange's certificate of listing | Feb 4, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 4, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| F-1/A · Registration statement, amended | Feb 1, 2021 |
| UPLOAD · Letter from the SEC | Jan 28, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 22, 2021 |
| CORRESP · Letter to the SEC | Jan 22, 2021 |
| F-1/A · Registration statement, amended | Jan 22, 2021 |
| F-1 · Registration statement | Jan 15, 2021 |
| UPLOAD · Letter from the SEC | Jan 15, 2021 |
| DRS/A · Draft registration statement, amended | Jan 11, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jan 11, 2021 |
| UPLOAD · Letter from the SEC | Jan 4, 2021 |
| DRSLTR · Letter to the SEC with a draft | Dec 18, 2020 |
| DRS/A · Draft registration statement, amended | Dec 18, 2020 |
| UPLOAD · Letter from the SEC | Dec 10, 2020 |
| DRS · Draft registration statement | Nov 12, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2021
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 252.3K | 150.2K | 80.5K | 8.44K | 614 | |||
| Gross profit | -252.3K | -150.2K | -80.5K | -8.44K | -614 | |||
| Research and development | 124.5M | 98.6M | 65.6M | 57.4M | 35.8M | 19.5M | 5.68M | 3.65M |
| Selling, general and administrative | 45.3M | 46.7M | 31.3M | 29.0M | 18.3M | 5.50M | 2.33M | 668.1K |
| Operating income | -173.7M | -132.4M | -99.8M | -75.7M | -42.7M | -26.1M | -8.03M | -4.31M |
| Depreciation and amortization | 418.4K | 269.6K | 257.6K | 152.9K | 77.4K | 7.40K | 549 | 0 |
| EBITDA | -173.3M | -132.1M | -99.6M | -75.5M | -42.6M | -26.1M | -8.03M | -4.31M |
| Interest expense | 20.1K | 16.1K | 267.5K | 92.5K | 16.9K | 380 | ||
| Income before tax | -173.7M | -132.4M | -99.8M | -75.7M | -42.7M | -26.1M | -8.03M | -4.31M |
| Income tax | 1.99M | 1.83M | 1.05M | 679.1K | 70.1K | -83.3K | 0 | 0 |
| Net income | -175.7M | -134.2M | -100.9M | -76.3M | -42.7M | -26.0M | -8.03M | -4.31M |
| Earnings per share, basic | -2.97 | -2.48 | -2.63 | -2.27 | -1.40 | -0.85 | -0.25 | -0.14 |
| Earnings per share, diluted | -2.97 | -2.48 | -2.63 | -2.27 | -1.40 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 291.7M | 280.7M | 391.2M | 161.8M | 209.4M | 98.6M | 20.3M | 5.39M | 4.80M |
| Short-term investments | 322.6K | ||||||||
| Receivables | 4.55M | 2.94M | 1.04M | 382.5K | 700.1K | 569.6K | 210.8K | 26.4K | 1.06K |
| Inventory | -322.6K | 4.04M | 1.51M | 540.7K | |||||
| Current assets | 299.2M | 289.4M | 397.9M | 166.8M | 211.6M | 101.0M | 20.6M | 5.43M | 4.80M |
| Property, plant and equipment | 642.5K | 667.0K | 223.7K | 193.5K | 108.1K | 48.5K | 12.9K | 0 | |
| Total assets | 301.5M | 291.4M | 398.7M | 167.7M | 212.1M | 101.1M | 20.6M | 5.43M | 4.80M |
| Accounts payable | 5.11M | 4.56M | 2.91M | 6.69M | 2.49M | 830.9K | 517.8K | 246.4K | 60.5K |
| Current liabilities | 29.6M | 23.0M | 14.6M | 18.2M | 6.99M | 5.31M | 1.92M | 481.3K | 138.8K |
| Total debt | 776.8K | 861.5K | 238.9K | 436.8K | 250.2K | ||||
| Total liabilities | 30.2M | 23.6M | 14.6M | 18.5M | 7.14M | 5.31M | 1.92M | 481.3K | 138.8K |
| Shareholders' equity | 271.3M | 267.8M | 384.0M | 149.3M | 205.0M | 95.8M | 18.7M | 4.95M | 4.66M |
| Shares outstanding | 59.2M | 54.0M | 38.4M | 33.6M | 30.4M | 30.5M | 31.8M | 31.8M | 30.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -137.1M | -120.1M | -93.0M | -67.2M | -44.6M | -21.5M | -6.68M | -3.92M |
| Capital spending | -164.6K | -538.1K | -90.0K | -124.3K | -130.0K | -43.0K | -13.5K | 0 |
| Free cash flow | -137.2M | -120.7M | -93.1M | -67.3M | -44.7M | -21.5M | -6.69M | -3.92M |
| Cash from investing | -164.6K | -538.1K | -90.0K | -124.3K | -130.0K | -43.0K | -13.5K | 0 |
| Cash from financing | 160.6M | 2.68M | 325.4M | 8.65M | 143.7M | 101.2M | 21.6M | 4.51M |
| Change in cash | 23.4M | -118.0M | 232.3M | -58.6M | 98.9M | 79.7M | 14.9M | 590.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 23, 2026 | Other filings | SEC |
Show 200 filings
This page holds 200 of 332 filings. Open Filings
Cap table
Built by 6ix from Pharvaris N.V.’s releases · as of Jul 24, 2025
- Common shares
- 70,204,506
- Fully diluted
- 70,204,506
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 70,204,506 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 70,204,506 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Meeker Other companies: Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past) | Chair of the Board · Since at least Mar 18, 2026 |
| Berndt Modig Other companies: Sio Gene Therapies Inc (Director · Apr 29, 2016 – Apr 15, 2021 · Past) | Chief Executive Officer, Director · Since at least Mar 17, 2026 |
| Elisabeth Björk Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Apr 20, 2020) | Director · Since at least Mar 18, 2026 |
| Viviane Monges Other companies: ADC Therapeutics SA (Non-Executive Director · Since at least Jun 1, 2026) | Director · Since at least May 21, 2026 |
| Anna Nijdam | Head, Strategic Finance and Principal Accounting Officer · Since at least Apr 1, 2026 |
| Anne Lesage | Chief Early Development Officer · Since at least Mar 18, 2026 |
| Annick Deschoolmeester | Chief Human Resources Officer · Since at least Mar 18, 2026 |
| David Nassif | Chief Financial Officer & Chief Legal Officer · Since at least May 21, 2026 |
| Hans Schikan | Vice Chair of the Board · Since at least Nov 5, 2026 |
| Johannes Gerardus Christiaan Petrus Schikan | Director · Since at least Mar 17, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Maggie Beller | Vice President, Head of Corporate and Investor Communications · Since at least Sep 8, 2026 |
| Peng Lu | President · Since at least Mar 18, 2026 |
| Peng Lu | President · Since at least Oct 5, 2026 |
| Robert Glassman | Director · Since at least Mar 17, 2026 |
| Stefan Abele | Chief Technical Operations Officer · Since at least Mar 18, 2026 |
| Wim Souverijns | Chief Commercial Officer · Since at least Jan 13, 2025 |
Log in to ask 6ix AI your own questions about Pharvaris N.V.